CytRx Closes SynthRx Deal
CytRx said this week that it has closed its deal to exclusively license its phase III sickle cell disease drug Flocor, as well as its OptiVax vaccine delivery technology, to SynthRx, a Houston-based startup firm founded and run by Robert Hunter, a CytRx co-founder and chairman of the University of Texas' department of pathology and laboratory medicine.
The assets were leftovers from the time before CytRx acquired Global Genomics and was repositioned as an RNAi therapeutics firm.